Consensus $611.09M. The company said, “Inspire is increasing and narrowing its full year 2023 revenue guidance to between $608 million to $612 million, which represents growth of 49% to 50% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $600 million to $610 million. The Company is maintaining its full year 2023 gross margin guidance of 83% to 85%. Inspire is also maintaining its guidance relating to the opening of new U.S. medical centers of 52 to 56 per quarter for the remaining quarter of the year, as well as its guidance of 12 to 14 new U.S. territories for the fourth quarter of 2023.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical price target lowered to $250 from $350 at Stifel
- LivaNova price target lowered to $62 from $71 at Needham
- Inspire Medical price target lowered to $180 from $355 at BofA
- Inspire Medical price target lowered to $300 from $380 at Mizuho
- Inspire Medical initiated with a Market Perform at Leerink